Mankind Pharma
Ticker > Company >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  1.61 L   464   115

2560.00
-36.20 (-1.39%)
BSE: 23 Sep 04:01 PM

Price Summary

Today's High

₹ 2616.2

Today's Low

₹ 2552

52 Week High

₹ 3050

52 Week Low

₹ 2115.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 105666.17 Cr.

Enterprise Value

₹ 112425.99 Cr.

No. of Shares

41.28 Cr.

P/E

58.25

P/B

7.04

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  363.64

CASH

₹ 305.87 Cr.

DEBT

₹ 7065.69 Cr.

Promoter Holding

72.68 %

EPS (TTM)

₹  43.95

Sales Growth

10.07%

ROE

15.52 %

ROCE

17.05%

Profit Growth

6.3 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Mankind Pharma Ltd.

Moxikind Mahacef Zenflox Cefakind Telmikind Amlokind Zolahart Overzyme Pantakind Ranidom Asthakind Combihale Nurokind Nurokind Plus Nurokind Gold Health OK Dynaglipt Glimestar Glykind-M Voglistar Unwanted-21 Days Prega News AcneStar Ring-Out Daffy Codistar Clonafit Manforce Epic Health OK Unwanted-72 AcneStar Kabz End Ring-Out Safe Kind Kaloree-1 Heal-O-Kind Calsimust Gel Multistar Liquid Calcimust Strong Liquid Nurokind-Plus Vet Injection Enerdyna Liquid Totavit Strong Powder Ceftiforce Injection Enrostrong

Index Presence

The company is present in 26Indices.

NIFTYMIDCAP

NIFTY Midcap 100
58496.6
  -202.900000000001 (-0.345658821625394%)

NIFTY500

Nifty 500
23325.25
  -56.2000000000007 (-0.240361483141549%)

NIFTYPHARMA

Nifty Pharma
22299.1
  -66.6500000000015 (-0.298000290622946%)

NIFTYMIDCAP150

Nifty Midcap 150
21713.6
  -63.9000000000015 (-0.293422109975894%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20118.5
  -75.1500000000015 (-0.372146689677211%)

NFTMIDSMLINCONS

Nifty MidSmall India Consumption
19804.85
  -106.5 (-0.53487081488699%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17943.75
  -59.7999999999993 (-0.332156713537046%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16388.2
  -39.4500000000007 (-0.2401439037233%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16261.55
  -48.25 (-0.29583440630786%)

NIFTYHEALTH

Nifty Healthcare Index
14659.05
  -62.5 (-0.424547686894383%)

NFT500EQUAL

Nifty 500 Equal Weight
14551.35
  -58.1999999999989 (-0.398369559637357%)

NIFTY200

Nifty 200
14087.2
  -30.1999999999989 (-0.213920410273838%)

NIFTYTOTALMCAP

Nifty Total Market index
13129.5
  -31.8500000000004 (-0.241996451731774%)

SHARIAH500

Nifty500 Shariah
7151.6
  -44.25 (-0.614937776635149%)

BSE HC

S&P Bse Healthcare
44573.59
  -195.93 (-0.437641502522257%)

BSE500

S&P Bse 500
36631.9
  -75.9700000000012 (-0.206958344355046%)

200EQW

BSE 200 Equal Weight
13208.45
  -34.75 (-0.262398815996134%)

BSE200

S&P Bse 200
11458.18
  -19.8899999999994 (-0.173286972461395%)

BSE1000

Bse 1000
10917.19
  -23.1099999999988 (-0.211237351809357%)

LMI250

S&P Bse 250 LargeMidCap
10888.02
  -20.0399999999991 (-0.183717361290636%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

LRGCAP

S&P Bse LargeCap
9732.85
  -16.0399999999991 (-0.164531551797165%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
9326.91
  -15.7900000000009 (-0.16900895886629%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

BSESELECTIPO

BSE Select IPO Index
4985.71
  -31.6000000000004 (-0.629819564667133%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.07%
3 Year8.26%
5 Year14.65%

Profit Growth

1 Year3.69%
3 Year11.87%
5 Year15.22%

ROE%

1 Year15.52%
3 Year17.75%
5 Year20.75%

ROCE %

1 Year17.05%
3 Year21.14%
5 Year25.88%

Debt/Equity

0.4841

Price to Cash Flow

45.5

Interest Cover Ratio

7.1942

CFO/PAT (5 Yr. Avg.)

1.03836759904079

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 72.68 0.00
Mar 2025 72.70 0.00
Dec 2024 72.71 0.00
Sep 2024 74.87 0.00
Jun 2024 74.87 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.138% over the past 3 years.
  • The Company has been maintaining an effective average operating margins of 23.8395717247582% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -4.06270000000001 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.03836759904079.
  • The company has a high promoter holding of 72.68%.

 Limitations

  • The company has shown a poor revenue growth of 8.25627937334403% for the Past 3 years.
  • The company is trading at a high PE of 58.25.
  • The company is trading at a high EV/EBITDA of 36.2422.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 2412.62 2529.74 2396.57 2126.59 2541.36
Total Expenditure 1836.58 1777.71 1655.64 1649.67 1868.29
Operating Profit 576.04 752.03 740.93 476.92 673.07
Other Income 96.04 105.76 69.82 219.32 64.22
Interest 6.63 1.92 199.47 162.25 146.7
Depreciation 91.33 85.42 87.03 105.24 96.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 574.12 770.45 524.25 428.75 493.66
Tax 97.7 168.01 107.87 46.29 80.9
Profit After Tax 476.42 602.44 416.38 382.46 412.76
Adjusted EPS (Rs) 11.89 15.04 10.09 9.27 10

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 5523.18 7486.22 8127.15 8629.25 9497.8
Total Expenditure 4151.05 5647.73 6429.29 6362.36 6934.73
Operating Profit 1372.13 1838.49 1697.86 2266.89 2563.07
Other Income 154.5 203.81 162.78 270.5 493.21
Interest 8.23 47.54 28.23 16.93 372.28
Depreciation 78.19 123.33 269.58 335.26 378.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 1440.21 1871.44 1562.84 2185.2 2305.99
Tax 355.83 482.01 314.58 412.57 421.74
Net Profit 1084.37 1389.42 1248.26 1876.16 1945.48
Adjusted EPS (Rs.) 27.07 34.68 31.16 44.25 45.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 40.06 40.06 40.06 40.06 41.26
Total Reserves 4694.21 6500.39 7743.85 9662.71 14599.01
Borrowings 0 0 0 0 4942.69
Other N/C liabilities 54.11 126.98 168.12 197.06 153.84
Current liabilities 1078.91 2271.27 1419.09 1616.56 4091.52
Total Liabilities 5867.29 8938.7 9371.12 11516.39 23828.32
Assets
Net Block 981.95 2921.3 3136.89 3546.28 3470.75
Capital WIP 165.51 355.28 437.83 134.74 191.36
Intangible WIP 0.06 31.28 56.95 74.7 16.07
Investments 1500.86 1657.08 2040.76 1975.85 15124.52
Loans & Advances 115.59 146.3 148.86 142.85 182.22
Other N/C Assets 16.04 14.45 36.1 15.12 150.09
Current Assets 3087.28 3813.01 3513.72 5626.85 4693.31
Total Assets 5867.29 8938.7 9371.12 11516.39 23828.32
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1440.21 1871.44 1562.84 2325.72 2390.36
Adjustment 96.74 -4.16 227 164.74 339.35
Changes in Assets & Liabilities -156.19 -585.61 294.21 -333.38 63.93
Tax Paid -397.38 -460.22 -285.06 -421 -471.48
Operating Cash Flow 983.38 821.44 1798.99 1736.08 2322.16
Investing Cash Flow -1127.16 -1360.27 -1040.61 -1665.19 -12178.83
Financing Cash Flow 88.87 578.63 -710.41 -4.73 9845.34
Net Cash Flow -54.91 39.81 47.96 66.16 -11.33

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 74.87 74.87 72.71 72.70 72.68
arjun juneja 2.04 2.04 1.98 1.98 1.98
chanakya juneja 0.97 0.97 0.94 0.94 0.94
eklavya juneja 0.97 0.97 0.94 0.94 0.94
mishka arora 0.74 0.74 0.72 0.72 0.72
poonam juneja 2.64 2.64 2.56 2.56 2.56
prem sheetal family trust... 15.41 15.41 14.97 14.97 14.96
puja juneja 2.88 2.88 2.80 2.80 2.79
rajeev juneja 1.62 1.62 1.58 1.58 1.57
rajeev juneja family trus... 19.95 19.95 19.37 19.37 19.37
ramesh juneja 1.71 1.71 1.66 1.66 1.66
ramesh juneja family trus... 20.81 20.80 20.20 20.20 20.20
ria chopra juneja 0.32 0.32 0.31 0.31 0.31
sheetal arora 4.81 4.81 4.67 4.67 4.67
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 25.13 25.13 27.29 27.30 27.32
axis mutual fund trustee ... - - - - 1.17
government pension fund g... - 1.11 1.54 1.52 1.63
nps trust a/c - sbi pensi... - - - - 1.59
sbi healthcare opportunit... - - - - 1.45
sbi life insurance co. lt... - - - 1.05 1.07
axis mutual fund trustee ... 1.28 - 1.06 1.29 -
nps trust- a/c sbi pensio... - - - 1.02 -
sbi large & midcap fund 1.50 - - 1.58 -
sbi nifty 500 index fund - - 1.67 - -
sbi nifty midcap 150 inde... - 1.49 - - -
tata aia life insurance c... - 1.08 - - -
hema cipef (i) limited 1.62 - - - -
icici prudential mutual f... 1.00 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit ICRA
Credit ICRA
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY25
Presentation H1FY24

Company News

Mankind Pharma incorporates wholly owned subsidiary in Russia 19 Aug, 4:58 PM Mankind Pharma reports 18% fall in Q1 consolidated net profit 1 Aug, 12:28 PM Mankind Pharma - Quaterly Results 31 Jul, 5:04 PM Mankind Pharma - Quaterly Results 31 Jul, 5:04 PM Mankind Pharma - Quaterly Results 31 Jul, 5:04 PM Mankind Pharma informs about allotment of equity shares 10 Jun, 12:31 PM Mankind Pharma gets ESG score of 38.98 from ISS ESG 5 Jun, 10:30 AM Mankind Pharma reports 11% fall in Q4 consolidated net profit 22 May, 12:30 PM Mankind Pharma gets nod to incorporate wholly owned subsidiary in Sri Lanka 22 May, 11:09 AM Mankind Pharma - Quaterly Results 21 May, 6:05 PM Mankind Pharma - Quaterly Results 21 May, 6:05 PM Mankind Pharma informs about conference call 12 May, 5:34 PM Mankind Pharma gets nod to incorporate wholly owned subsidiary in Russia 15 Apr, 10:30 AM Mankind Pharma informs about compliances certificate 3 Apr, 5:10 PM Mankind Pharma informs about disclosure 1 Mar, 4:05 PM Mankind Pharma informs about outcome of board meeting 10 Feb, 5:28 PM Mankind Pharma - Quaterly Results 23 Jan, 7:18 PM Mankind Pharma - Quaterly Results 23 Jan, 7:18 PM Mankind Pharma informs about update 15 Jan, 10:10 AM Mankind Pharma, Innovent Biologics partner to commercialise Sintilimab 27 Dec, 11:18 AM Mankind Pharma informs about updates 20 Dec, 3:46 PM Mankind Pharma informs about disclosure 15 Nov, 10:38 AM Mankind Pharma informs about newspaper publication 6 Nov, 5:04 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma submits intimation of board meeting 25 Oct, 5:20 PM Mankind Pharma completes transaction to acquire 100% stake in Bharat Serums and Vaccines 24 Oct, 9:39 AM Mankind Pharma informs about allotment of non-convertible debentures 16 Oct, 4:08 PM Mankind Pharma to transfer OTC business undertaking to MCPPL 4 Sep, 9:29 AM Mankind Pharma informs about presentation 20 Aug, 9:38 AM Mankind Pharma informs about allotment under ESOP 14 Aug, 5:13 PM Mankind Pharma informs about investors meet 7 Aug, 11:57 AM Mankind Pharma’s Q1FY25 consolidated net profit surges by 10% 31 Jul, 3:57 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma inks pact to acquire 100% stake in BSV 26 Jul, 10:30 AM Mankind Pharma informs about change in time of conference call 26 Jul, 9:58 AM Mankind Pharma informs about newspaper advertisement 10 Jul, 2:05 PM Mankind Pharma informs about transcript of conference call 22 May, 5:12 PM Mankind Pharma informs about newspaper publication 16 May, 4:51 PM Mankind Pharma reports 62% rise in Q4 consolidated net profit 16 May, 12:22 PM Mankind Pharma gets nod to raise funds through various modes 16 May, 11:38 AM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma informs about allotment under ESOP 10 May, 9:45 AM Mankind Pharma informs about investor meetings 14 Mar, 12:48 PM Mankind Pharma informs about press release 11 Mar, 4:57 PM

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Mankind Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Mankind Pharma has a PE ratio of 58.3469096138269 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Mankind Pharma has ROA of 10.6621% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Mankind Pharma has a Current ratio of 1.1471.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Mankind Pharma has a ROE of 15.5235%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Mankind Pharma has a Debt to Equity ratio of 0.4841 which means that the company has low proportion of debt in its capital.

  • Sales growth: Mankind Pharma has reported revenue growth of 10.0652% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Mankind Pharma for the current financial year is 26.9859335846196%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Mankind Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Mankind Pharma is Rs 43.9492. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Mankind Pharma in Ticker for free. Also, one can get the intrinsic value of Mankind Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Mankind Pharma FAQs

Q1. What is Mankind Pharma share price today?
Ans: The current share price of Mankind Pharma is Rs 2564.3.

Q2. What is the market capitalisation of Mankind Pharma?
Ans: Mankind Pharma has a market capitalisation of Rs 105843.6595907 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Mankind Pharma?
Ans: The PE ratio of Mankind Pharma is 58.3469096138269 and the P/B ratio of Mankind Pharma is 7.05183593034569, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Mankind Pharma share?
Ans: The 52-week high share price of Mankind Pharma is Rs 3054.8, and the 52-week low share price of Mankind Pharma is Rs 2115.1.

Q5. Does Mankind Pharma pay dividends?
Ans: Currently, Mankind Pharma does not pay dividends. Dividend yield of Mankind Pharma is around 0%.

Q6. What are the face value and book value of Mankind Pharma shares?
Ans: The face value of Mankind Pharma shares is Rs 1, while the book value per share of Mankind Pharma is around Rs 363.6358. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Mankind Pharma?
Ans: Mankind Pharma has a total debt of Rs 7065.69 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Mankind Pharma?
Ans: The ROE of Mankind Pharma is 15.5235% and ROCE of Mankind Pharma is 17.0462%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Mankind Pharma a good buy for the long term?
Ans: The Mankind Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Mankind Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Mankind Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Mankind Pharma’s financials?
Ans: You can review Mankind Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Mankind Pharma

Mankind Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Mankind Pharma Ltd. is a reputed pharmaceutical company that specializes in the development, production, and marketing of high-quality generic medicines. Established in XXXX, the company has since grown to become one of the leading players in the Indian pharmaceutical industry. Mankind Pharma operates with a vision to provide affordable and accessible healthcare solutions to people across the globe.

Mankind Pharma Ltd. - Share Price

Check the latest share price of Mankind Pharma Ltd. and stay updated with real-time market fluctuations. Our pre-built screening tools allow you to track the stock price, monitor trends, and make informed investment decisions.

Mankind Pharma Ltd. - Balance Sheet

The balance sheet of Mankind Pharma Ltd. provides a snapshot of the company's financial position. Analyze the company's assets, liabilities, and equity to gain insights into its overall financial health. We offer premium features such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis to help you calculate fair value.

Mankind Pharma Ltd. - Annual Report

Access the annual reports of Mankind Pharma Ltd. on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Gain valuable insights into the company's strategies, growth trajectory, and competitive advantage.

Mankind Pharma Ltd. - Dividend

Stay updated with the company's dividend history and payout ratios. Mankind Pharma Ltd. has a track record of consistently rewarding its shareholders through dividends. Our website provides downloadable resources such as dividend history and financial statements for your analysis.

Mankind Pharma Ltd. - Quarterly Result

Get access to the latest quarterly results of Mankind Pharma Ltd. Track the company's revenue, profit, and other key financial metrics to gauge its performance. Our premium features enable you to analyze these results in conjunction with our comprehensive tools for fair value calculation.

Mankind Pharma Ltd. - Stock Price

Monitor the stock price of Mankind Pharma Ltd. and keep track of its historical performance. Our price charts provide a visual representation of the stock's movement over time. Utilize our pre-built screening tools to identify trends, patterns, and potential investment opportunities.

Mankind Pharma Ltd. - News

Stay updated with the latest news and developments related to Mankind Pharma Ltd. Our website provides curated news articles that cover the company's activities, regulatory updates, product launches, and industry trends. Stay informed and make well-informed investment decisions.

Mankind Pharma Ltd. - Concall Transcripts

Access the conference call transcripts of Mankind Pharma Ltd. These transcripts provide a detailed account of the discussions and presentations made during the company's conference calls. Stay informed about management's outlook, strategic initiatives, and future plans.

Mankind Pharma Ltd. - Investor Presentations

Explore the investor presentations of Mankind Pharma Ltd. These presentations offer valuable insights into the company's operations, growth prospects, and market dynamics. Access downloadable resources on our website to stay updated with the latest investor presentations.

Mankind Pharma Ltd. - Promoters

Learn about the promoters of Mankind Pharma Ltd. and their contribution to the company's success. Understand their vision, leadership style, and strategic direction to assess the stability and long-term potential of the company.

Mankind Pharma Ltd. - Shareholders

Discover the major shareholders of Mankind Pharma Ltd. and their significance in the company's ownership structure. Gain insights into the involvement of institutional investors and public shareholders, which play a crucial role in determining the company's governance and market dynamics.

Remember to visit our website for downloadable resources such as annual reports, concall transcripts, investor presentations, credit ratings, and research reports. Our pre-built screening tools and premium features provide you with the necessary tools to analyze and make informed investment decisions.

Read More
X